ArticleScientific reports2026
Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Tumor Mutational Landscape and Its Correlation With Histopathological Characteristics in Breast Cancer.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The application of advanced next-generation sequencing (NGS) technologies in the analysis of circulating tumor DNA (ctDNA) enabled the comprehensive evaluation of tumor-derived alterations in the bloodstream. In this study, we evaluated the analytical performance and clinical utility of a large-scale liquid biopsy assay in patients with metastatic cancer. A total of 1,110 unique patients underwent ctDNA NGS testing using a 1021-gene panel; matched tissue biopsy data were available for 145 cases. In 16.18% of the cases, at least one on-label variant was identified. In addition, off-label, clinical trial–related, and resistance-associated findings collectively increased the proportion of clinically actionable results by 40.65%. Importantly, 8.65% of the total population could also benefit from immune checkpoint inhibitors (ICI) therapy, based on the high tumor mutational burden (TMB-H) and/or high microsatellite instability (MSI-H) status. Simultaneous analysis in plasma and white blood cells enabled clonal hematopoiesis-associated variants detection, hence increasing the specificity value for ctDNA analysis and confirming the presence of pathogenic germline variants for 11.26% patients. Of interest, concordance for actionable on-label candidates using tissue and plasma analysis was 90.34%, thereby confirming the reliability of liquid biopsy results. Notably, the combination of liquid biopsy analysis, and tissue-based profiling, increased the total number of actionable biomarkers, facilitating targeted therapy and immunotherapy selection, resistance monitoring, and faster clinical decision-making. The broad genomic coverage of the liquid biopsy NGS assay used enabled clinically meaningful genomic characterization across multiple tumor histological types, although tumor-specific generalization is limited by the heterogeneity of the tumor types analyzed. Overall, this study shows that large-scale LB profiling may increase the number of actionable findings detected beyond guideline-based targets. In addition, it provides a more accurate understanding of tumor biology and ctDNA shedding in circulation, while offering the advantage of parallel germline analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.